pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 30·1 min read
save

A decade after WHO recognition, mycetoma is still one of the world’s most neglected diseases

Jul 30, 2026·read at STAT ↗Negative

Borna Nyaoke-Anoke, a physician leading mycetoma work at the Drugs for Neglected Diseases initiative, reflects on a decade since the World Health Organization formally acknowledged the disease.

She recounts meeting Tesfaye, a man from north‑central Ethiopia who first felt a thorn in his foot as a teenager. The injury later developed into mycetoma, a chronic infection that erodes skin, tissue and bone, often ending in amputation and severe social stigma.

Mycetoma is caused by certain fungi or bacteria and has been reported in more than 100 countries across Africa, Asia and Latin America. Despite its wide reach, the condition remains largely ignored by health systems, leaving patients to rely on traditional healers who lack effective treatments.

Although WHO recognition a ten‑year ago sparked some research advances, progress is fragile. Nyaoke‑Anoke warns that the next decade will determine whether mycetoma stays a story of neglect or becomes a model of coordinated global action.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases”

read at STAT ↗
1,230 words · retrieved Jul 30
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADINGThe Medicines Co
drugs
itraconazole
topics
Dermatology3Infectious Disease2Orthopedics2Alzheimer's DiseaseDiagnostics CompanyOphthalmologySmall Molecule

related stories

  • 5h agoSionna says good-bye to 46% of staffers, including execBioSpace
  • Sep 3Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readoutFierce Biotech
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: RegCell wrangles $66M; Encoded finagles $275M series FFierce Biotech
  • Aug 28FDA green lights Priovant drug for rare skin diseaseBioPharma Dive